RSNA 2022 Ultrasound Preview

Road to RSNA 2022: Ultrasound Preview

By Amerigo Allegretto, staff writer
November 21, 2022

Ultrasound's versatility will be on display at RSNA 2022, with research presentations highlighting the modality's use in breast, musculoskeletal, pediatric, and other imaging applications.

Look for presentations on ultrasound in applications such as liver cancer detection, breast lesion evaluation, arthritis diagnosis, and ovarian mass characterization, among other areas. Contrast-enhanced ultrasound (CEUS) will be highlighted for women's imaging and molecular imaging.

Other methods of ultrasound will also be discussed, including shear wave elastography's potential in musculoskeletal imaging as well as volume sweep imaging's use in breast imaging. On the treatment side of things, several talks will feature use of MR-guided focused ultrasound for osteoma treatment and prostate cancer diagnosis.

RSNA 2022 attendees will also have the opportunity to attend various education sessions exploring the latest innovations and techniques in sonography. These include case reports, updates in neonatal imaging, pediatric oncology and emergency medicine, advanced ultrasound technology and applications, artificial intelligence in ultrasound imaging, contrast agent use, and more.

Keep reading for highlights in ultrasound coming from the annual meeting, and you can also view the complete 2022 scientific and educational program on the RSNA website.

Ultrasound may not be needed for women with fatty breast density
Monday, November 28 | 1:30 p.m.-2:30 p.m. | M6-SSBR04-5 | E451A
Here, research findings will show that ultrasound may not be needed to help detect breast cancer in women with fatty breast density.
How impactful are changes to carotid ultrasound recommendations?
Tuesday, November 29 | 1:30 p.m.-2:30 p.m. | T6-SSNR08-5 | E350
The effects of revised guidelines for the use of carotid Doppler ultrasound in diagnosing internal carotid artery stenosis will be discussed in this RSNA presentation.
CEUS earns high marks in detecting liver cancer
Tuesday, November 29 | 1:30 p.m.-2:30 p.m. | T6-SSGI11-1 | S404
In this presentation, researchers will review the effectiveness of contrast-enhanced ultrasound (CEUS) for detecting liver cancer when using different classification systems.
Ultrasound is cost-effective in evaluating recalled breast lesions
Tuesday, November 29 | 3:00 p.m.-4:00 p.m. | T7-SSBR07-5 | E450B
In this presentation, research will show how using ultrasound first to assess noncalcified lesions recalled by digital breast tomosynthesis (DBT) is cost-effective and can improve patient quality of life.
Elastography helps measure tissue stiffness in tendinopathy patients
Wednesday, November 30 | 9:30 a.m.-10:30 a.m. | W3-SSMK08-1 | E451A
This session will discuss findings from a pilot study showing that using elastography shear-wave imaging to evaluate Achilles tendon stiffness could be good for research on tendon remodeling, healing, and return to activity.
Ultrasound molecular imaging can characterize ovarian masses
Wednesday, November 30 | 1:30 p.m.-2:30 p.m. | W6-SSOB02-6 | E353C
Ultrasound molecular imaging (USMI) using a clinical-grade contrast agent shows promise for characterizing ovarian masses, according to this scientific presentation.
Is MR-HIFU safe for treating patients with osteoid osteoma?
Thursday, December 1 | 8:00 a.m.-9:00 a.m. | R1-SSMK10-1 | E451A
In this presentation, research will highlight the safety and efficacy of MR-guided high-intensity focused ultrasound (MR-HIFU) when it comes to treating osteoid osteoma close to sensitive body structures.
Could volume sweep imaging assist in breast cancer detection?
Thursday, December 1 | 9:30 a.m.-10:30 a.m. | R3-SSIN07-3 | S404
A new system that automatically detects palpable breast lumps without the need of a sonographer or radiologist will be explained in this RSNA session.
B-mode breast ultrasound can aid in predicting treatment response
Thursday, December 1 | 1:30 p.m.-2:30 p.m. | R6-SSBR11-6 | E451B
B-mode breast ultrasound can aid in predicting response to neoadjuvant chemotherapy, according to this scientific presentation.